Drug Trial Radar · NCT03337724
A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Last checked: Nov 19, 2026Latest source record: Mar 12, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
579
Actual
Start
Jan 6, 2018
Primary completion
Jan 4, 2023
Study completion Jan 4, 2023
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 9, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy of ipatasertib + paclitaxel versus placebo + paclitaxel in participants with histologically confirmed, locally advanced or metastatic triple-negative breast cancer (TNBC) and in participants with locally advanced or metastatic hormone receptor positive (HR+)/ human epidermal growth factor receptor 2 negative (HER2-) breast adenocarcinoma who are not suitable for endocrine therapy.
Conditions
- Breast Cancer
Interventions
IpatasertibDrug
Ipatasertib, 400 milligrams (mg), administered orally once a day (QD) on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
PaclitaxelDrug
Paclitaxel, 80 mg/square meter (m\^2), administered intravenously (IV) on Days 1, 8, and 15 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
PlaceboDrug
Matching placebo, administered orally QD on Days 1-21 of each 28-day cycle until disease progression, intolerable toxicity, elective withdrawal from the study, or study completion or termination.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cohort A: Progression-Free Survival (PFS)Time frame: From randomization up to 27 months
- Cohort B: PFSTime frame: From randomization up to 24.4 months
- Cohort C: PFSTime frame: From enrollment up to 31 months
Locations
176 sites in 30 countries. Site status is shown where the registry gives one.
UCSD Moores Cancer Center
La Jolla, California
USC Norris Cancer Center
Los Angeles, California
USC Norris Cancer Center; USC Oncology Hematology Newport Beach
Newport Beach, California
Kaiser Permanente - Oakland
Oakland, California
Kaiser Permanente - Roseville
Roseville, California
UC Davis; Comprehensive Cancer Center
Sacramento, California
Kaiser Permanente Sacramento Medical Center
Sacramento, California
Kaiser Permanente - San Francisco (2238 Geary)
San Francisco, California
UCSF Comprehensive Cancer Ctr
San Francisco, California
K. Permanente - San Jose
San Jose, California
Kaiser Permanente - San Leandro
San Leandro, California
K. Permanente - Santa Clara
Santa Clara, California
Kaiser Permanente - South San Francisco
South San Francisco, California
Kaiser Permanente - Vallejo
Vallejo, California
K. Permanente - Walnut Creek
Walnut Creek, California
Memorial Regional Hospital
Hollywood, Florida
Mount Sinai Comprehensive Cancer Center
Miami Beach, Florida
UF Health Cancer Center at Orlando Health
Orlando, Florida
Memorial Hospital West
Pembroke Pines, Florida
University of Maryland
Baltimore, Maryland
Mercy Medical Center
Baltimore, Maryland
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland
Memorial Sloan Kettering Cancer Center at Westchester
Harrison, New York
Memorial Sloan Kettering
New York, New York
West Clinic
Germantown, Tennessee
Texas Oncology, P.A.
Dallas, Texas
UT Southwestern Medical Center; Simmons Comprehensive Cancer Center, Simmons Pharmacy
Dallas, Texas
Oncology Consultants PA
Houston, Texas
Fundación CENIT para la Investigación en Neurociencias
Buenos Aires, Argentina
Hosp Provincial D. Centenarios; Oncology Dept
Rosario, Argentina
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
Calvary Mater Newcastle; Medical Oncology
Waratah, New South Wales, Australia
Westmead Hospital; Medical Oncology
Wentworthville, New South Wales, Australia
Mater Hospital; Cancer Services
South Brisbane, Queensland, Australia
Cabrini Medical Centre; Oncology
Malvern, Victoria, Australia
Fiona Stanley Hospital; FSH Cancer Centre Clinical Trials Unit
Bull Creek, Western Australia, Australia
Cliniques Universitaires St-Luc
Brussels, Belgium
GHdC Site Notre Dame
Charleroi, Belgium
UZ Leuven Gasthuisberg
Leuven, Belgium
Santa Casa de Misericordia de Salvador
Salvador, Estado de Bahia, Brazil
Showing 40 of 176 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.